YHR2401

YHR2401 is an investigational pharmaceutical product developed by Yuhan Corporation. It has been studied in phase 1 clinical trials as part of a bioequivalence study comparing it to another compound, YHP2205, in healthy volunteers. The specific active ingredient, mechanism of action, and therapeutic indication for YHR2401 have not been disclosed in publicly available sources. The primary focus of the referenced studies is to determine whether the pharmacokinetic profiles of YHP2205 and YHR2401 are equivalent when administered orally to healthy subjects[1][2][3][5][7]. No information about its molecular modality or target is currently available.